Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 1997

View Archived Issues

FDA wants stronger warning labels for fen/phen

Review of fenfluramines points to neurotoxicity

Disappointing phase III trial results with interferon gamma for atopic dermatitis

Faulding's generic acyclovir receives FDA approval

Mayo Clinic, Wyeth-Ayerst plan fen/phen study

DIAMOND CHF study results reported

FDA approves Gensia's injectable acyclovir

Seven studies published on Emdogain

SYST-EUR trial results presented

Panretin trial in KS halted early

Notice of allowance for LHRH vaccine patent

FKBP12 inhibitors in the pipeline at Guilford

Innothera discloses more agents for venous function deficiency

P&U cephem derivatives for inhibiting HLE

Stromelysin inhibitors: New approach to treating arthritis?

Kos Pharmaceuticals: Q4 and year-end highlights

Cortecs granted patent for Flustat

Novopharm Biotech, Genesys Pharma receive approval to amalgamate

Pharos receives patent for novel method of controlling and treating inflammation

Inex: Q2 1997 highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...